A new frontier for medical device trust and patient safety

Tern plc

As clinical environments become increasingly digital and interconnected, medical devices no longer operate in isolation. They link into hospital networks, share data across platforms, interface with cloud services and increasingly fall under regulatory scrutiny. That means the device manufacturers and healthcare providers face new challenges, including how to establish trust, how to manage devices through their lifecycle, and how to ensure compliance with evolving standards. Device Authority’s KeyScaler platform presents itself as a technology to address exactly these challenges in the realm of the Internet of Medical Things (IoMT).

At a fundamental level the platform begins with device trust. Each device must be registered, authenticated and clearly identified before it transmits patient data or interfaces with clinical systems. Once that trust anchor is in place, KeyScaler automates credential issuance and lifecycle management so that as devices are deployed, maintained, updated or retired the identity and certificate infrastructure is managed at scale.

Connected devices are generating streams of sensitive patient information, system telemetry and operational metrics. Encryption, secure updates and policy‑driven access become mandatory. The KeyScaler platform emphasises end‑to‑end encryption, including the ability to manage data both at rest and in transit, and to enforce policies on how and when keys can be used.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search